ScripThe number of initial public offerings in the US by biopharmaceutical companies in 2023 may be able to at least match the number of IPOs in 2022 now that another company has made its stock market debu
ScripThe once-shocking $100m-plus venture capital round is not such a shock anymore in the biopharmaceutical sector, since the number of mega-rounds has increased over the last few years as drug developmen